Parkinson's psychosis

Current Treatment Options in Neurology

Volumn 12, Issue 3, 2010, Pages 200-211

  Zahodne, Laura B ^a   Fernandez, Hubert H ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; GALANTAMINE; MEMANTINE; OLANZAPINE; ONDANSETRON; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; TACRINE; ZIPRASIDONE;

COGNITIVE THERAPY; DRUG CONTRAINDICATION; DRUG TOLERABILITY; HUMAN; MOTOR PERFORMANCE; PARKINSON DISEASE; PSYCHOSIS; REVIEW;

EID: 77953544355     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0072-y     Document Type: Review

References (70)

1. Zahodne LB, Fernandez HH: Pathophysiology and management of psychosis in Parkinson's disease: a review. Drugs Aging 2008, 25:665-682. This is an easy-to-read, updated review of the pathophysiology and management of psychosis in PD.
2. Fenelon G, Mahieux F, Huron R, Ziegler M: Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000, 123:733-745.
3. Goetz CG, Fan W, Leurgans S, et al.: The malignant course of "benign hallucinations" 208 Movement Disorders in Parkinson disease. Arch Neurol 2006, 63:713-716.
4. Ramirez-Ruiz B, Junque C, Marti MJ, et al.: Cognitive changes in Parkinson's disease patients with visual hallucinations. Dement Geriatr Cogn Disord 2007, 23:281-288. (Pubitemid 46631933)
5. Moskovitz C, Moses H, Klawans HL: Levodopainduced psychosis: a kindling phenomenon. Am J Psychiatry 1978, 135:669-675.
6. Pappert EJ, Goetz CG, Niederman FG, et al.: Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov Disord 1999, 14(1):117-121.
7. Carter JH, Stewart BJ, Archbold PG, et al.: Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord 1998, 13:20-28.
8. Goetz CG, Stebbins GT: Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993, 43:2227-2229.
9. Goetz CG, Tanner CM, Klawans HL: Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 1982, 139:494-497.
10. Fenelon G, Goetz CG, Karenberg A: Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006, 66:93-98.
11. Goetz CG, Fan W, Leurgans S: Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov Disord 2008, 15:1541-1545.
12. Parkinson Study Group: Low dose clozapine for the treatment of drug-induced psychosis in idiopathic Parkinson's disease: results of the double blind, placebo controlled PSYCLOPS trial. N Engl J Med 1999, 340:757-763.
13. French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999, 353:2041-2042.
14. Klein C, Gordon J, Pollak L, et al.: Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol 2003, 26:8-11.
15. Reddy S, Factor SA, Molho ES, et al.: The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002, 17:676-681.
16. Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003, 18:510-514.
17. Ondo WG, Tintner R, Voung KD, et al.: Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergicinduced hallucinations in Parkinson's disease. Mov Disord 2005, 20(8):958-963.
18. Rabey JM, Prokhorov T, Miniovich A, et al.: The effect of quetiapine in Parkinson's disease (PD) psychotic patients: a double-blind labeled study of three months duration. Mov Disord 2005, 20:S46.
19. Morgante L, Epifanio A, Spina E, et al.: Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004, 27:153-156.
20. Fernandez HH, Okun MS, Rodriguez RL, et al.: Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci 2009, 119(12):2196-2205. This is the only double-blind, randomized positive clinical trial on quetiapine for PD psychosis.
21. Ford B, Lynch T, Greene P: Risperidone in Parkinson's disease. Lancet 1994, 344:681.
22. Meco G, Alessandria A, Bonifati V, et al.: Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994, 343:1370-1371.
23. Workman Jr RH, Orengo CA, Bakey AA, et al.: The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997, 9:594-597.
24. Rich SS, Friedman JH, Ott BR: Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995, 56:556-559.
25. Mohr E, Mendis T, Hildebrand K, et al.: Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000, 15:1230-1237.
26. Meco G, Alessandri A, Giustini P, et al.: Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997, 12:610-612.
27. Ellis T, Cudkowicz ME, Sexton PM, et al.: Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000, 12:364-369.
28. Fernandez HH, Trieschmann ME, Friedman JH: The treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003, 26:643-659.
29. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996, 47:1085-1087.
30. Breier A, Sutton VK, Feldman PD, et al.: Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002, 52:438-445.
31. Ondo WG, Levy JK, Vuong KD, et al.: Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord 2002, 17:1031-1035.
32. Goetz CG, Blasucci LM, Leurgans S, et al.: Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000, 55:789-794.
33. Schonfeldt-Lecuona C, Connemann BJ: Aripiprazole and Parkinson's disease psychosis. Am J Psychiatry 2004, 161:373-374.
34. Wickremaratchi M, Morris HR: Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006, 21:1538-1539.
35. Lopez-Meza E, Ruiz-Chow A, Ramirez-Bermudez J: Aripiprazole in psychosis associated with Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005, 17:421-422.
36. Fernandez HH, Trieschmann ME, Friedman JH: Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004, 27:4-5.
37. Friedman JH, Berman RM, Goetz CG, et al.: Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006, 21:2078-2081.
38. Connemann BJ, Schonfeldt-Lecuona C: Ziprasidone in Parkinson's disease psychosis. Can J Psychiatry 2004, 49:73.
39. Shiah I-S, Lin C-L, Mao W-C, Luu S-U: Ziprasidone in the treatment of Parkinson's disease psychosis. Eur Psychiatry 2006, 21:578-579.
40. Oechsner M, Korchounov A: Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005, 20:203-205.
41. Weiden PJ, Iqbal N, Mendelowitz AJ, et al.: Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002, 8:81-97.
42. Burn D, Emre M, McKeith I, et al.: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006, 21:1899-1907.
43. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 2001, 16:1171-1174.
44. Bullock R, Cameron A: Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin 2002, 18:258-264.
45. Fabbrini G, Barbanti P, Aurilia C, et al.: Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002, 23:41-43.
46. Bergman J, Lerner V: Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 2002, 25:107-110.
47. Kurita A, Ochiai Y, Kono Y, et al.: The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003, 16:184-188.
48. Ravina B, Putt M, Siderowf A, et al.: Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005, 76:934-939.
49. Aarsland D, Laake K, Larsen J, et al.: Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 2002, 72:708-712.
50. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 1996, 61:324-325.
51. Ott B, Lannon M: Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992, 15:322-325.
52. Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003, 18:937-941.
53. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY: Efficacy and safety of galantamine for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol 2008, 38:937-945.
54. Zoldan J, Friedberg G, Goldberg-Stern H, et al.: Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993, 341:562-563.
55. Zoldan J, Friedberg G, Livneh M, et al.: Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995, 45:1305-1308.
56. Eichhorn TE, Brunt E, Oertel WH: Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996, 47:1608-1609.
57. Winblad B, Jones RW, Wirth Y, et al.: Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomized clinical trials. Dement Geriatr Cogn Disord 2007, 24:20-27.
58. Gauthier S, Wirth Y, Mobius HJ: Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized controlled studies. Int J Geriatr Psychiatry 2005, 20:459-464.
59. Cummings JL, Schneider E, Tariot PN: Graham SM; the Memantine MEM-MD-02 Study Group: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006, 67:57-63.
60. Sleeper RB: Antipsychotic dose-sparing effect with addition of memantine. Ann Pharmacother 2005, 39:1573-1576.
61. Ridha BH, Josephs KA, Roosor MN: Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005, 65:481-482.
62. Monastero R, Camarda C, Pipia C, Camarda R: Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. J Neurol Neurosurg Psychiatry 2007, 78:546.
63. Meco G, Bernardi S: Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prof Neuropsychopharmacol Biol Psychiatry 2007, 31:311-313.
64. Voon V, Lang AE: Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. Clin Neuropharmacol 2004, 27:90-92.
65. Lauterbach EC: Dopaminergic hallucinosis with fluoxetine in Parkinson's disease. Am J Psychiatry 1993, 150:1750.
66. Normann C, Hesslinger B, Frauenknecht S, et al.: Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry 1997, 30:263-265.
67. Factor SA, Molho ES, Brown DL: Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998, 50:1456-1458.
68. Diederich NJ, Pieri V, Goetz CG: Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003, 18:831-838.
69. Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008, 34:523-537.
70. Zimmermann G, Favrod J, Trieu VH, Pomini V: The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta analysis. Schizophr Res 2005, 77 (1):1-9.